(10alpha)-2alpha,3alpha,16alpha,20,25-五羟基-9beta-甲基-19-去甲羊毛甾-5-烯-11,22-二酮 | 25383-26-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: (10alpha)-2alpha,3alpha,16alpha,20,25-五羟基-9beta-甲基-19-去甲羊毛甾-5-烯-11,22-二酮
• 英文名称: Cucurbitacin P
• 英文别名: (2R,3S,8S,9R,10R,13R,14S,16R,17R)-17-[(2R)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,3,16-trihydroxy-4,4,9,13,14-pentamethyl-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one
• CAS: 25383-26-0
• 化学式: C₃₀H₄₈O₇
• 分子量: 520.7
• InChiKey: VVBWBGOEAVGFTN-SYJGCRHZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  135
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES
  申请人：Anji Pharma (US) LLC

  公开号：EP2661266B1

  公开（公告）日：2020-09-16
• Chemosensory Receptor Ligand-Based Therapies
  申请人：BARON Alain D.

  公开号：US20120177730A1

  公开（公告）日：2012-07-12

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
• US9050292B2
  申请人：——

  公开号：US9050292B2

  公开（公告）日：2015-06-09
• US9463170B2
  申请人：——

  公开号：US9463170B2

  公开（公告）日：2016-10-11
• US9962344B2
  申请人：——

  公开号：US9962344B2

  公开（公告）日：2018-05-08